search
Back to results

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Primary Purpose

Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
PTK787/ZK 222584
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Von Hippel-Lindau Disease focused on measuring von Hippel-Lindau disease,, CNS,, hemangioblastoma,, retinal

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: Confirmed diagnosis of VHL disease One or more measurable CNS hemangioblastoma, if symptomatic, must be refractory or not amenable to standard therapy, if asymptomatic, must have had at least one prior neurosurgical treatment/ procedure; and/or: at least one untreatable or treatment-refractory retinal hemangioblastoma that is causing impaired visual function Karnofsky Performance Status >=60 Life expectancy > 3 months Able to sign informed consent Adequate hematologic status, liver and kidney function Exclusion criteria: Patients with other VHL-related tumors requiring or amenable to standard treatment Severe or uncontrolled concurrent illnesses that could compromise participation in the study Total urinary protein in 24 hour collection > 500 mg Pregnant or breast feeding females, adults of reproductive potential not using effective contraception (hormonal methods not considered effective due to possible decreased effectiveness secondary to drug interaction with PTK787). Women of childbearing potential must have negative serum pregnancy test prior to initiation of treatment. Acute or chronic liver disease Diagnosis of HIV infection GI function that may alter absorption of PTK787 Patients taking coumadin (warfarin sodium) Prior therapies (investigational drugs, chemotherapy) within 4 weeks prior to study entry Prior therapies (biologic, hormonal, immunotherapy, radiation therapy, surgery) within two weeks prior to study entry. Patients unwilling or unable to comply with protocol requirements Patients with concurrent, non VHL-related malignancies other than non-melanoma skin cancer Patients with contraindication to MRI imaging

Sites / Locations

  • Dana Farber Cancer Institute
  • Duke University Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PTK787/ZK 222584

Arm Description

Outcomes

Primary Outcome Measures

Evaluate efficacy

Secondary Outcome Measures

Evaluate changes in dynamic contrast enhanced magnetic resonance imaging
To explore the correlation of the pharmacokinetics
To assess changes in surrogate markers of angiogenesis

Full Information

First Posted
January 21, 2003
Last Updated
March 2, 2017
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00052013
Brief Title
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Official Title
A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients With Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2011
Overall Recruitment Status
Completed
Study Start Date
February 2003 (undefined)
Primary Completion Date
June 2006 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine whether PTK787/ZK 222584 is effective in treating hemangioblastoma of the brain and/or retina in patients with von Hippel-Lindau disease. The study will also assess safety and tolerability of PTK787/ZK 222584, and changes in markers of angiogenesis (new blood vessel growth).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma
Keywords
von Hippel-Lindau disease,, CNS,, hemangioblastoma,, retinal

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PTK787/ZK 222584
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
PTK787/ZK 222584
Primary Outcome Measure Information:
Title
Evaluate efficacy
Secondary Outcome Measure Information:
Title
Evaluate changes in dynamic contrast enhanced magnetic resonance imaging
Title
To explore the correlation of the pharmacokinetics
Title
To assess changes in surrogate markers of angiogenesis

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Confirmed diagnosis of VHL disease One or more measurable CNS hemangioblastoma, if symptomatic, must be refractory or not amenable to standard therapy, if asymptomatic, must have had at least one prior neurosurgical treatment/ procedure; and/or: at least one untreatable or treatment-refractory retinal hemangioblastoma that is causing impaired visual function Karnofsky Performance Status >=60 Life expectancy > 3 months Able to sign informed consent Adequate hematologic status, liver and kidney function Exclusion criteria: Patients with other VHL-related tumors requiring or amenable to standard treatment Severe or uncontrolled concurrent illnesses that could compromise participation in the study Total urinary protein in 24 hour collection > 500 mg Pregnant or breast feeding females, adults of reproductive potential not using effective contraception (hormonal methods not considered effective due to possible decreased effectiveness secondary to drug interaction with PTK787). Women of childbearing potential must have negative serum pregnancy test prior to initiation of treatment. Acute or chronic liver disease Diagnosis of HIV infection GI function that may alter absorption of PTK787 Patients taking coumadin (warfarin sodium) Prior therapies (investigational drugs, chemotherapy) within 4 weeks prior to study entry Prior therapies (biologic, hormonal, immunotherapy, radiation therapy, surgery) within two weeks prior to study entry. Patients unwilling or unable to comply with protocol requirements Patients with concurrent, non VHL-related malignancies other than non-melanoma skin cancer Patients with contraindication to MRI imaging
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis
Organizational Affiliation
Novartis
Official's Role
Study Chair
Facility Information:
Facility Name
Dana Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

We'll reach out to this number within 24 hrs